A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT07216703 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1023

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Sacituzumab Tirumotecan
BIOLOGICAL: Bevacizumab
DRUG: Paclitaxel
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Rescue Medications

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]
[object Object]